NCT00835536已完成1 期
A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Non-Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 2
- 主要终点
- Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
研究概览
简要总结
The objective of this study is to compare the relative bioavailability of ribavirin 200 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of COPEGUS™ 200 mg tablets (Roche) in healthy, adult, non-smoking, females (who are unable to become pregnant) under non-fasting conditions.
详细描述
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •All subjects selected for this study will be non-smokers, at least 18 years of age, and a female whi is physically unable to become pregnant (postmenopausal for at least 6 months or surgically sterile). Subjects will have a BMI (body mass index) of 30 or less.
- •Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes but is not limited to, blood pressure, general observations, and history.
- •Each subject will be given a serum pregnancy test as part of the pre-study screening process.
- •Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trial for clinical laboratory measurements.
- •Clinical laboratory measurements will include the following:
- •Hematology: hemoglobin, hematocrit, red blood cell count, platelets, and white blood cell count with differential.
- •Clinical Chemistry: creatinine, BUN, glucose, SGOT/AST, SGPT/ALT, bilirubin, and alkaline phosphatase.
- •Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and cells.
- •HIV Screen: pre-study only
- •Hepatitis-B, C Screen: pre-study only
- •Drugs of Abuse Screen: (pre-study and at each check-in)
- •Subjects will be selected if all above are normal.
排除标准
- •Subjects with a significant recent history of chronic alcohol consumption (past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma (past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
- •Subjects whose clinical laboratory test values are greater than 20% outside the normal range may be retested. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator dems the result to not be significant.
- •Subjects who have a history of allergic responses to the class of drug being tested will be excluded from the study.
- •Subjects who use tobacco in any form will not be eligible to participate in the study. Three months abstinence is required.
- •All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each dosing period check-in. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate.
- •Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study.
- •Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
- •Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study will not be allowed to participate.
- •All female subjects will be screened for pregnancy at check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study.
- •Subjects who do not tolerate venipuncture will not be allowed to participate.
研究组 & 干预措施
1
Experimental
干预措施: Ribavirin 200 mg tablets (Drug)
2
Active Comparator
干预措施: COPEGUS™ 200 mg Tablets (Drug)
结局指标
主要结局
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
时间窗: Blood samples collected over a 72 hour period.
Bioequivalence based on Cmax.
AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time of 72 Hours)
时间窗: Blood samples collected over a 72 hour period.
Bioequivalence based on AUC0-72.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Ribavirin 200 mg Tablets Under Fasting ConditionsHealthyNCT00835146Teva Pharmaceuticals USA28
已完成
1 期
Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting ConditionsChronic Hepatitis CNCT00960479Sandoz38
已完成
1 期
Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting ConditionsChronic Hepatitis CNCT00959933Sandoz24
已完成
1 期
Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male SubjectsHealthyNCT02251158Boehringer Ingelheim30
已完成
1 期
A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy VolunteersHealthy VolunteerNCT01592318Hoffmann-La Roche42